Reporter brief
Role of Exercise and Low-Dose Rapamycin on Age-Associated Impairments in Older Adults With Coronary Artery Disease: Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol describing a planned trial, not a completed study with results—no efficacy or safety data are reported
- The pilot phase sample size is very small (up to 18 total, with only 6 per dose group), limiting ability to detect effects or establish safe dosing
- The decision to proceed to Phase 2 depends on unspecified criteria for 'favorable changes' in senescent markers, introducing bias into trial initiation
Study design and sample
Rct; Human.
Patients aged 60 years or older with coronary artery disease undergoing percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), or eligible to participate in cardiac rehabilitation
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Dec 7, 2016
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.